Fannin Innovation Studio

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Fannin Innovation Studio is Houston's most active life sciences development group focused exclusively on commercializing biotech and medtech technologies. Fannin creates and manages start-ups to develop internal and in-licensed assets and programs through clinical proof-of-concept. Fannin has over a dozen active programs, including three in clinical development.

Programs we will share include Pulmotect, developing an anti-COVID-19 therapy in Phase 2 clinical trials; Allterum, developing an anti-IL-7 antibody for the treatment of pediatric T-Cell ALL; ATCG, developing next-generation aptamers (Raptamers) for several indications incuding oncology, opthalmology, and auto-immunity; Encephallay, developing brain-penetrant selective PDE4B inhibitors; Brimstalt, developing targeted anti-cancer therapeutics, and Brevitest, our point-of-care robotic ELISA platform.

For more information, please visit www.fannininnovation.com
Company Type:
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
PUL-042 (Pulmotect)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
12
Speaker
photo
Managing Partner
Fannin Innovation Studio